|
|
|||
|
| |||
|
| |||
|
| |||
|
|
|||
|
Takayuki Kogure, Yoshiyuki Ueno, Yuta Wakui, Takao Iwasaki, Tooru Shimosegawa, Division of Gastroenterology, Graduate School of Medicine, Tohoku University, Sendai 980-8574, Japan Satoshi Sekiguchi, Division of Advanced Surgical Science and Technology, Graduate School of Medicine, Tohoku University, Sendai 980-8574, Japan Kazuyuki Ishida, Department of Pathology, Tohoku University Hospital, Sendai 980-8574, Japan Takehiko Igarashi, Division of Gastroenterology Osaki Citizen Hospital, Furukawa 989-6183, Japan Author contributions: Kogure T, Ueno Y and Wakui Y participated in writing of the manuscript; Kogure T, Ueno Y, Iwasaki T, Shimosegawa T, Sekiguchi S, Ishida K, and Igarashi T participated in treatment of the patient. Correspondence to: Yoshiyuki Ueno, MD, PhD, Division of Gastroenterology, Graduate School of Medicine, Tohoku University, 1-1 Seiryo, Aoba-ku, Sendai 980-8574, Japan. yueno@mail.tains.tohoku.ac.jp Telephone: +81-22-7177171 Fax: +81-22-7177177 Received: September 25, 2008 Revised: November 1, 2008 Accepted: November 8, 2008 Published online: March 14, 2009
Abstract A liver tumor 35 mm in diameter was found incidentally in a 40-year-old woman who had no history of liver diseases or the use of oral contraceptives. Radiological diagnostics showed the typical findings of liver cell adenoma (LCA). Dynamic computed tomography revealed that the tumor showed a homogenous enhancement in the arterial phase and almost the same enhancement as the surrounding liver parenchyma in the delayed phase. The tumor was found to contain fat on magnetic resonance imaging. A benign fat containing liver tumor was suggested. However, radiological findings altered, which caused us to suspect that a well-differentiated hepatocellular carcinoma (HCC) containing fat was becoming dedifferentiated. Partial hepatectomy was performed and the pathological findings showed the typical findings of LCA. This case was an extremely rare LCA, which had no background of risk for LCA and developed the sequential alteration of the radiological findings to suspect well-differentiated HCC.
© 2009 The WJG Press and Baishideng. All rights reserved.
Key words: Liver cell adenoma; Hepatocellular carcinoma; Diagnosis; Hepatectomy
Peer reviewers: Dr. Natalie J Torok, UC Davis Medical Center, Patient Support Services Building, 4150 V Street, Suite 3500, Sacramento, CA 95817, United States; Dr. Serdar Karakose, Professor, Department of Radiology, Meram Medical Faculty, Selcuk University, Konya 42080, Turkey
Kogure T, Ueno Y, Sekiguchi S, Ishida K, Igarashi T, Wakui Y, Iwasaki T, Shimosegawa T. Liver cell adenoma showing sequential alteration of radiological findings suggestive of well-differentiated hepatocellular carcinoma. World J Gastroenterol 2009; 15(10): 1267-1272 Available from: URL: http://www.wjgnet.com/1007-9327/15/1267.asp DOI: http://dx.doi.org/10.3748/wjg.15.1267
INTRODUCTION Liver cell adenoma (LCA) is a benign tumor of the liver parenchyma that is associated with the use of oral contraceptives or with glycogen-storage disease[1]. The occurrence of LCA in patients without such backgrounds is extremely rare[2]. We report a case of LCA found in a 40-year-old woman without a history of oral contraceptive use in which the sequential alteration of the radiological findings suggested well-differentiated hepatocellular carcinoma (HCC).
CASE REPORT In November 2006, a 40-year-old woman developed lower abdominal pain and was admitted to a hospital. The patient had no history of liver disease, alcohol consumption, oral contraceptive use, nor the use of any other medication. The family history of the patient was not noteworthy. The patient was diagnosed as having a left tubo-ovarian abscess and tubo-ovariectomy was performed. The resected ovary and oviduct showed the findings of endometriosis with bacterial infection, but there was no indication of neoplastic lesion. At this time, a space-occupying lesion (SOL) 35 mm in diameter was found in the liver by abdominal ultrasonography and computed tomography (CT). In the CT, the lesion in the liver (segment 8) showed slight low density by plain examination and an enhancing effect by the contrast agent. In the magnetic resonance imaging (MRI), the SOL showed almost isointensity on T1 and slightly high intensity on T2 (Figure 1A-B). Superparamagnetic iron-oxide (SPIO)-MRI indicated that the SOL did not show most of the SPIO uptake (Figure 1C). On the gadolinium-enhanced T1, the SOL indicated a slight homogenous enhancement in the arterial phase, and almost the same enhancement as the surrounding liver parenchyma in the delayed phase (Figure 1D-G). The SOL showed almost isointensity on the in-phase-T1 and slightly low intensity on the opposed-phase-T1, which indicated that the SOL contained a fat component (Figure 1-H, 1-I). A capsule or scars were not detected in the SOL. A benign, fat containing tumor was suggested. The dynamic CT in March 2007 showed that the SOL had not changed in size (Figure 2). The SOL indicated low density by plain examination, showed a slight homogenous enhancing effect in the arterial phase, and, an enhancing effect that was slightly lower than the surrounding liver in the delayed phase (Figure 2). In the dynamic CT after four months, the density of the SOL on plain examination was elevated and the enhancing effect in the arterial phase increased slightly, although the size and the form of the SOL did not show apparent changes (Figure 3). Because of the alteration of the findings in this CT, we suspected that the findings were suggestive of well-differentiated HCC. In August 2007, the patient was referred to our hospital for further examination and treatment. The physical examination of the patient showed no abnormal findings. The blood test indicated no abnormalities including liver related enzymes except slight iron deficiency anemia (Table 1). All the hepatitis virus markers were negative. There were no abnormal findings suggestive of autoimmune liver disease or metabolic liver disease including glycogen-storage disease. Hepatic arteriography was performed and the nodule presented with a slight tumor stain in the arterial phase and the hepatic parenchymal phase, and it did not show an apparent drainage vein (Figure 4). Positron emission tomography showed no difference in accumulation between the nodule and the surrounding hepatic parenchyma and no abnormal accumulation suspicious of malignant tumors in other organs. No abnormal findings were found suggesting a primary tumor in other organs in whole-body CT. Digestive tract endoscopy showed no abnormal findings. Taken together, the above-mentioned findings suggested the possibility that the nodule was a well-differentiated HCC that was dedifferentiating. After receiving informed consent, partial hepatectomy was performed on August 28, 2007. The pathological finding (Figure 5) revealed the following. Hepatocytes more lucent than that of the surrounding hepatic parenchyma had proliferated thickly in the nodule. Hepatocytes did not show severe cellular atypia. Exclusion of the surrounding hepatic parenchyma was apparent, but direct invasion to the surrounding was not seen. The nodule did not contain the portal tracts and bile ducts. Myogenic arteries, large lipid droplets, hemorrhage and degeneration were seen in the nodule. The surrounding hepatic parenchyma had no abnormal findings except fatty change with large lipid droplets around the nodule. Thus, we diagnosed the nodule as a LCA.
DISCUSSION LCA is considered a rare benign tumor of the liver and is distinguished from solitary tumors and adenomatosis[3,4]. LCA was a very rare tumor until an association with oral contraceptives was reported. Before 1954, only two cases were detected among 5000 autopsies in 36 years[5]. The association with oral contraceptives was thoroughly described in the 1970s[6,7], and many cases of LCA have been reported since[8-10]. Due to the progress of diagnostic imaging techniques, the typical findings of LCA have been identified[4,11]. A typical LCA shows low density or isodensity on plain CT, presents a homogenous contrasting effect on arterial phase and does not show an apparent wash out on delayed phase. A typical LCA in MRI shows almost the same signal intensity as the surrounding parenchyma on T1 and T2 and shows high intensity on fat suppression T2. LCA may often present difficulties in a differential diagnosis with well-differentiated HCC and focal nodular hyperplasia[12-14]. The pathological findings of a typical LCA include the following[2,10,15-17]: (1) the tumor consists of hepatocytes with almost normal nuclei and cytoplasm presenting a homogenous increase, (2) and does not include the portal area and bile duct, (3) hepatocytes form hepatic cords, but sinusoids are pressed, and hepatic lobule structure is absent, (4) the tumor includes macrovesicular fatty changes, hemorrhage, degeneration, and myogenic arteries. LCA can be divided into three categories: (1) LCA associated with oral administration of medicines including oral contraceptives and steroids[8-10], (2) LCA developing as a complication of glycogen-storage diseases[18-20], (3) adenomatosis[3,4,15]. Solitary LCAs are most frequently caused by oral contraceptives[7,21]. The occurrence of adenomatosis is unrelated to the use of oral contraceptives and the frequency of development is not related to sex[15]. It is reported that LCA occurs in patients of glycogen-storage disease type Ⅰ[19]. In addition to oral contraceptives, oral administrations of such medications as clomiphene[22], barbituric acid[23] or androgen[24,25] are reported as risk factors for LCA. Also, it is reported that LCAs associated with oral contraceptives show regression after discontinuing the drug[26,27]. The main complications of LCA include tumor hemorrhage and malignant transformation. It is reported that hemorrhage is found in about one half of LCAs and can result in death[9,16,28]. Malignant transformation of LCA is considered to be rare. However, in several reported cases, LCA associated with glycogen-storage diseases and glucocorticosteroids developed HCC[29-32]. In another reported case, hepatocarcinogenesis occurred several years after discontinuation of oral contraceptives[32]. Although LCA is a benign liver tumor, treatment is often conducted to avoid hemorrhage and malignant transformation[3,4]. Surgical treatments such as lobectomy[21,33], enucleation[34] and liver transplantation[35] are performed for LCA. Percutaneous ethanol injection[20] and transcatheter arterial embolization[33] are established therapies for low invasive treatment of HCC, and were reported to be performed for LCA. However, precise pathological examination is not possible by these treatments. Since a definitive diagnosis of LCA by diagnostic imaging alone or by needle biopsy is difficult[11], tumor resection is often the most suitable approach. Our case was found by chance during treatment of the endometriosis complicated with bacterial infection. The patient did not have a history of using oral contraceptives or glucocorticosteroids which are known risk factors for LCA. Nor did the patient have metabolic liver disease including glycogen-storage disease. By MRI, the tumor was found to contain fat. In dynamic studies, the tumor showed a homogenous enhancement in the arterial phase and almost the same enhancement as the surrounding liver parenchyma in the delayed phase. These findings were typical for LCA. However, the tumor showed an elevation of the density on plain CT and an increase of the early enhancement in the arterial phase, which caused us to suspect that well-differentiated HCC containing fat was becoming dedifferentiated. Accordingly, hepatic resection was performed. In a prospective study of 48 LCA cases reported by van der Windt et al[27], serial observation was considered appropriate for tumors with the typical image findings of LCA if the diameter was less than 5 cm. Five of the 48 cases of LCA were resected because the radiological findings changed during serial observations and three of the five cases had well-differentiated HCC, while in the remaining two cases, it was difficult to distinguish between well-differentiated HCC and LCA pathologically. The present case showed the typical radiological findings for LCA and was 35 mm in diameter without an increasing tendency. However, diagnosis only by radiological findings is difficult in patients without a background supporting a diagnosis of LCA such as a history of receiving the above mentioned drugs or glycogen-storage disease. Resection of the tumor in the present case was therefore considered appropriate because of the risk of hemorrhage and possible malignant transformation.
REFERENCES 1 Brophy CM, Bock JF, West AB, McKhann CF. Liver cell adenoma: diagnosis and treatment of a rare hepatic neoplastic process. Am J Gastroenterol 1989; 84: 429-432 PubMed 2 Kerlin P, Davis GL, McGill DB, Weiland LH, Adson MA, Sheedy PF 2nd. Hepatic adenoma and focal nodular hyperplasia: clinical, pathologic, and radiologic features. Gastroenterology 1983; 84: 994-1002 PubMed DOI 3 Chiche L, Dao T, Salamé E, Galais MP, Bouvard N, Schmutz G, Rousselot P, Bioulac-Sage P, Ségol P, Gignoux M. Liver adenomatosis: reappraisal, diagnosis, and surgical management: eight new cases and review of the literature. Ann Surg 2000; 231: 74-81 PubMed 4 Grazioli L, Federle MP, Ichikawa T, Balzano E, Nalesnik M, Madariaga J. Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients. Radiology 2000; 216: 395-402 PubMed 5 Edmondson HA. Tumors of the liver and intrahepatic bile ducts. In: Atlas of tumor pathology. Washington DC: Armed Forces Institute of Pathology, 1958 6 Baum JK, Bookstein JJ, Holtz F, Klein EW. Possible association between benign hepatomas and oral contraceptives. Lancet 1973; 2: 926-929 PubMed 7 Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 1976; 294: 470-472 PubMed 8 Helling TS, Wood WG. Oral contraceptives and cancer of the liver: a review with two additional cases. Am J Gastroenterol 1982; 77: 504-508 PubMed 9 Meissner K. Hemorrhage caused by ruptured liver cell adenoma following long-term oral contraceptives: a case report. Hepatogastroenterology 1998; 45: 224-225 PubMed 10 Shortell CK, Schwartz SI. Hepatic adenoma and focal nodular hyperplasia. Surg Gynecol Obstet 1991; 173: 426-431 PubMed 11 Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A. Hepatic adenomas: imaging and pathologic findings. Radiographics 2001; 21: 877-892; discussion 892-984 PubMed 12 Charny CK, Jarnagin WR, Schwartz LH, Frommeyer HS, DeMatteo RP, Fong Y, Blumgart LH. Management of 155 patients with benign liver tumours. Br J Surg 2001; 88: 808-813 PubMed DOI 13 Herman P, Pugliese V, Machado MA, Montagnini AL, Salem MZ, Bacchella T, D'Albuquerque LA, Saad WA, Machado MC, Pinotti HW. Hepatic adenoma and focal nodular hyperplasia: differential diagnosis and treatment. World J Surg 2000; 24: 372-376 PubMed DOI 14 Cherqui D, Rahmouni A, Charlotte F, Boulahdour H, Métreau JM, Meignan M, Fagniez PL, Zafrani ES, Mathieu D, Dhumeaux D. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 1995; 22: 1674-1681 PubMed DOI 15 Lewin M, Handra-Luca A, Arrivé L, Wendum D, Paradis V, Bridel E, Fléjou JF, Belghiti J, Tubiana JM, Vilgrain V. Liver adenomatosis: classification of MR imaging features and comparison with pathologic findings. Radiology 2006; 241: 433-440 PubMed DOI 16 Erdogan D, Busch OR, van Delden OM, Ten Kate FJ, Gouma DJ, van Gulik TM. Management of spontaneous haemorrhage and rupture of hepatocellular adenomas. A single centre experience. Liver Int 2006; 26: 433-438 PubMed DOI 17 Giusti S, Donati F, Paolicchi A, Bartolozzi C. Hepatocellular adenoma: imaging findings and pathological correlation. Dig Liver Dis 2005; 37: 200-205 PubMed DOI 18 Fink AS, Appelman HD, Thompson NW. Hemorrhage into a hepatic adenoma and type Ia glycogen storage disease: a case report and review of the literature. Surgery 1985; 97: 117-124 PubMed 19 Parker P, Burr I, Slonim A, Ghishan FK, Greene H. Regression of hepatic adenomas in type Ia glycogen storage disease with dietary therapy. Gastroenterology 1981; 81: 534-536 PubMed DOI 20 Yoshikawa M, Fukui K, Kuriyama S, Tsujimoto T, Nakatani Y, Toyokawa Y, Kurematsu Y, Awata J, Shiroi A, Fukui H, Tsutsumi M. Hepatic adenomas treated with percutaneous ethanol injection in a patient with glycogen storage disease type Ia. J Gastroenterol 2001; 36: 52-61 PubMed 21 Leese T, Farges O, Bismuth H. Liver cell adenomas. A 12-year surgical experience from a specialist hepato-biliary unit. Ann Surg 1988; 208: 558-564 PubMed 22 Carrasco D, Barrachina M, Prieto M, Berenguer J. Clomiphene citrate and liver-cell adenoma. N Engl J Med 1984; 310: 1120-1121 PubMed 23 Vázquez JJ, Marigil MA. Liver-cell adenoma in an epileptic man on barbiturates. Histol Histopathol 1989; 4: 301-303 PubMed 24 Carrasco D, Pallardo L, Prieto M, Moll JL, Cruz JM, Berenguer J. Hepatic adenomata and androgen treatment. Ann Intern Med 1984; 100: 316 PubMed 25 Dourakis SP, Tolis G. Sex hormonal preparations and the liver. Eur J Contracept Reprod Health Care 1998; 3: 7-16 PubMed 26 Kawakatsu M, Vilgrain V, Erlinger S, Nahum H. Disappearance of liver cell adenoma: CT and MR imaging. Abdom Imaging 1997; 22: 274-276 PubMed 27 van der Windt DJ, Kok NF, Hussain SM, Zondervan PE, Alwayn IP, de Man RA, IJzermans JN. Case-orientated approach to the management of hepatocellular adenoma. Br J Surg 2006; 93: 1495-1502 PubMed DOI 28 Ameriks JA, Thompson NW, Frey CF, Appelman HD, Walter JF. Hepatic cell adenomas, spontaneous liver rupture, and oral contraceptives. Arch Surg 1975; 110: 548-557 PubMed 29 Burri E, Steuerwald M, Cathomas G, Mentha G, Majno P, Rubbia-Brandt L, Meier R. Hepatocellular carcinoma in a liver-cell adenoma within a non-cirrhotic liver. Eur J Gastroenterol Hepatol 2006; 18: 437-441 PubMed DOI 30 Ito M, Sasaki M, Wen CY, Nakashima M, Ueki T, Ishibashi H, Yano M, Kage M, Kojiro M. Liver cell adenoma with malignant transformation: a case report. World J Gastroenterol 2003; 9: 2379-2381 PubMed 31 Uto H, Shigehira M, Kawano T, Nagatomo H, Kuribayashi T, Taniguchi S, Koga K, Komada N, Kitamura T, Maruyama T, Tsubouchi H. Liver cell adenoma in a young man with elevated serum PIVKA-II level. J Gastroenterol 1996; 31: 441-445 PubMed 32 Gordon SC, Reddy KR, Livingstone AS, Jeffers LJ, Schiff ER. Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med 1986; 105: 547-549 PubMed 33 Ribeiro A, Burgart LJ, Nagorney DM, Gores GJ. Management of liver adenomatosis: results with a conservative surgical approach. Liver Transpl Surg 1998; 4: 388-398 PubMed DOI 34 Flejou JF, Barge J, Menu Y, Degott C, Bismuth H, Potet F, Benhamou JP. Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology 1985; 89: 1132-1138 PubMed DOI 35 Mueller J, Keeffe EB, Esquivel CO. Liver transplantation for treatment of giant hepatocellular adenomas. Liver Transpl Surg 1995; 1: 99-102 PubMed DOI
S- Editor Cheng JX L- Editor O’Neill M E- Editor Yin DH
| |||
|
|